Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease
Molecules · 30.10.2024 · 29 (21) · 5131
DOI: 10.3390/molecules29215131 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 30.10.2024. Verfasst von Amin Mahmood Thawabteh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Birzeit University, Birzeit P.O. Box 14, West Bank, Palestine. Hauptthemen laut MEDLINE: Alzheimer Disease. Die Arbeit wurde bisher 58-mal zitiert (Crossref) und nennt 221 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Demenz
Abstract (Originalsprache)
The most prevalent chronic neurodegenerative illness in the world is Alzheimer’s disease (AD). It results in mental symptoms including behavioral abnormalities and cognitive impairment, which have a substantial financial and psychological impact on the relatives of the patients. The review discusses various pathophysiological mechanisms contributing to AD, including amyloid beta, tau protein, inflammation, and other factors, while emphasizing the need for effective disease-modifying therapeutics that alter disease progression rather than merely alleviating symptoms. This review mainly covers medications that are now being studied in clinical trials or recently approved by the FDA that fall under the disease-modifying treatment (DMT) category, which alters the progression of the disease by targeting underlying biological mechanisms rather than merely alleviating symptoms. DMTs focus on improving patient outcomes by slowing cognitive decline, enhancing neuroprotection, and supporting neurogenesis. Additionally, the review covers amyloid-targeting therapies, tau-targeting therapies, neuroprotective therapies, and others. This evaluation specifically looked at studies on FDA-approved novel DMTs in Phase II or III development that were carried out between 2021 and 2024. A thorough review of the US government database identified clinical trials of biologics and small molecule drugs for 14 agents in Phase I, 34 in Phase II, and 11 in Phase III that might be completed by 2028.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Birzeit University, Birzeit P.O. Box 14, West Bank, Palestine.
- Faculty of Pharmacy, Nursing and Health Professions, Birzeit University, Birzeit P.O. Box 14, West Bank, Palestine.
- Pharmaceutical Sciences Department, Faculty of Pharmacy, Al-Quds University, Jerusalem 20002, Palestine.
- Department of Sciences, University of Basilicata, Via dell'Ateneo Lucano 10, 85100 Potenza, Italy.
ORCID-Profile: Amin Mahmood Thawabteh, Aseel Wasel Ghanem, Sara AbuMadi, Weam Jaghama, Rafik Karaman
Zitieren
APA
Thawabteh, A. M., Ghanem, A. W., AbuMadi, S., Thaher, D., Jaghama, W., Karaman, D., & Karaman, R. (2024). Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease. Molecules, 29(21), 5131. https://doi.org/10.3390/molecules29215131
Vancouver
Thawabteh AM, Ghanem AW, AbuMadi S, Thaher D, Jaghama W, Karaman D, et al. Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease. Molecules. 2024;29(21):5131. doi:10.3390/molecules29215131
BibTeX
@article{Thawabteh2024,
author = {Thawabteh, Amin Mahmood and Ghanem, Aseel Wasel and AbuMadi, Sara and Thaher, Dania and Jaghama, Weam and Karaman, Donia and Karaman, Rafik},
title = {Recent Advances in Therapeutics for the Treatment of Alzheimer’s Disease},
journal = {Molecules},
year = {2024},
volume = {29},
number = {21},
pages = {5131},
doi = {10.3390/molecules29215131}
}
EUVIMED